Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) has received a consensus recommendation of “Hold” from the eight ratings firms that are currently covering the stock, Marketbeat reports. Seven equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company.
A number of research analysts recently issued reports on BAYRY shares. Berenberg Bank lowered shares of Bayer Aktiengesellschaft from a “buy” rating to a “hold” rating in a research note on Wednesday, August 16th. Deutsche Bank Aktiengesellschaft lowered shares of Bayer Aktiengesellschaft from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. HSBC raised shares of Bayer Aktiengesellschaft from a “reduce” rating to a “hold” rating in a report on Tuesday, October 10th. They noted that the move was a valuation call. Finally, Redburn Atlantic downgraded shares of Bayer Aktiengesellschaft from an “overweight” rating to a “neutral” rating in a report on Monday, September 25th.
Bayer Aktiengesellschaft Stock Performance
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last posted its earnings results on Wednesday, November 8th. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 7.98% and a positive return on equity of 14.76%. The firm had revenue of $11.26 billion during the quarter, compared to analyst estimates of $12.62 billion. Equities analysts expect that Bayer Aktiengesellschaft will post 1.69 EPS for the current fiscal year.
Bayer Aktiengesellschaft Company Profile
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
- Five stocks we like better than Bayer Aktiengesellschaft
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- The most upgraded stocks in November have two things in common
- Best Stocks Under $5.00
- Monday.com rocked earnings like it’s the weekend
- What Does Downgrade Mean in Investing?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.